识别用于认知表现的新型治疗点,以及与大脑健康的关联
Lu-Yang Zhang1,2,3, Yu-Xin Liu1,2,3, Yun-Hui Chu1,2,3
1Department of Neurology, Tongji Hospital, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan, 430030, China.
Translational psychiatry
|June 25, 2025
概括
这项研究使用了门德尔的随机化方法,发现了72个可用药物的基因与认知表现有因果关系. 像ERBB3和CYP2D6这样的基因显示出对认知功能障碍和神经疾病的治疗点的希望.
科学领域:
- 遗传学 是一个遗传学.
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 认知功能障碍是一个重大的临床挑战,治疗选择有限.
- 目前的药物主要控制症状,而不是神经系统疾病中认知能力下降的潜在原因.
研究的目的:
- 通过使用孟德尔随机化 (MR) 来识别因果关系与认知表现相关的可药基因.
- 探索这些基因作为治疗治疗认知功能障碍和相关神经疾病的治疗点的潜力.
主要方法:
- 利用了对4302个具有血液和大脑cis表达量化特征位点 (eQTLs) 的可药物基因的MR和局部化分析.
- 评估候选基因对大脑结构和神经疾病发病率的因果关系.
- 整合遗传数据以识别影响认知表现的基因.
主要成果:
- 确定了72个可用药物的基因,与认知表现有因果关联 (41个血液eQTL,31个大脑eQTL).
- 突出了ERBB3 (血液和大脑eQTL) 和CYP2D6作为特别有前途的目标.
- 证实了这些基因对大脑结构和神经疾病的因果关系.
结论:
- 为改善认知功能提供了新的治疗点的遗传证据.
- 建议ERBB3和CYP2D6作为用于认知障碍药物开发的关键候选者.
- 阐明了将基因标与大脑结构和功能联系起来的潜在机制.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
214
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
214
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Alzheimer's Disease: Overview
684
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
684
Brain Imaging
321
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
321


